Intended for healthcare professionals only.

ZYDELIG (idelalisib) is a
PI3Kδ inhibitor indicated for

ZYDELIG (idelalisib) is a
PI3Kδ inhibitor indicated for

the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.1

Limitations of use1:

ZYDELIG is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas.

ZYDELIG is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas.

PI3Kδ=phosphatidylinositol 3-kinase.

ZYDELIG® efficacy

Results from final analysis of the pivotal trial 

View efficacy
Actor portrayal

ZYDELIG safety profile

Safety profile informed by multiple clinical studies

View details

ZYDELIG® AccessConnect®

Financial assistance for
ZYDELIG patients

Call to learn more
1-844-622-2377
Actor portrayal

Reference:

  1. ZYDELIG® (idelalisib) [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; rev February 2022.